A peptide CRF2 antagonist
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Antisauvagine-30 (trifluoroacetate salt)

Item No. 34271

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
D-phenylalanyl-L-histidyl-L-leucyl-L-leucyl-L-arginyl-L-lysyl-L-methionyl-L-isoleucyl-L-α-glutamyl-L-isoleucyl-L-α-glutamyl-L-lysyl-L-glutaminyl-L-α-glutamyl-L-lysyl-L-α-glutamyl-L-lysyl-L-glutaminyl-L-glutaminyl-L-alanyl-L-alanyl-L-asparaginyl-L-asparaginyl-L-arginyl-L-leucyl-L-leucyl-L-leucyl-L-α-aspartyl-L-threonyl-L-isoleucinamide, trifluoroacetate salt
Synonyms
  • AS30
  • D-FHLLRKMIEIEKNEKEKNNAANNRLLLDTI-NH2
  • [D-Phe11,His12]Svg11-40
  • aSVG
  • aSvg-30
Molecular Formula
C161H274N48O46S • XCF3COOH
Formula Weight
3650.3
Purity
≥95%
Formulation (Request formulation change)
A solid
Solubility(Learn about Variance in Solubility)
Water: soluble
SMILES
O=C([C@@H](CC1=CC=CC=C1)N)N[C@H](C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@]([H])([C@H](CC)C)C(N[C@H](C(N[C@@]([H])([C@H](CC)C)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](C)C(N[C@@H](C)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@H](C(N[C@]([H])(C(N[C@@]([H])([C@H](CC)C)C(N)=O)=O)[C@@H](C)O)=O)CC(O)=O)=O)=O)=O)=O)CCCNC(N)=N)=O)CC(N)=O)=O)CC(N)=O)=O)=O)=O)CCC(N)=O)=O)CCC(N)=O)=O)CCCCN[H])=O)CCC(O)=O)=O)CCCCN[H])=O)CCC(O)=O)=O)CCC(N)=O)=O)CCCCN[H])=O)CCC(O)=O)=O)=O)CCC(O)=O)=O)=O)CCSC)=O)CCCCN[H])=O)CCCNC(N)=N)=O)=O)=O)CC2=CNC=N2.OC(C(F)(F)F)=O
InChi Code
InChI=1S/C161H274N48O46S.C2HF3O2/c1-21-84(14)126(130(172)226)206-159(255)129(89(19)210)209-156(252)115(76-125(224)225)205-152(248)111(71-83(12)13)202-150(246)109(69-81(8)9)201-149(245)108(68-80(6)7)199-140(236)98(44-36-65-179-161(175)176)188-154(250)114(75-120(171)215)204-155(251)113(74-119(170)214)197-132(228)88(18)181-131(227)87(17)182-134(230)99(45-52-116(167)211)189-141(237)100(46-53-117(168)212)190-135(231)93(39-27-31-60-162)184-143(239)102(48-55-121(216)217)192-137(233)95(41-29-33-62-164)185-144(240)103(49-56-122(218)219)193-142(238)101(47-54-118(169)213)191-136(232)94(40-28-32-61-163)186-145(241)104(50-57-123(220)221)195-157(253)127(85(15)22-2)207-146(242)105(51-58-124(222)223)196-158(254)128(86(16)23-3)208-147(243)106(59-66-256-20)194-138(234)96(42-30-34-63-165)183-139(235)97(43-35-64-178-160(173)174)187-148(244)107(67-79(4)5)200-151(247)110(70-82(10)11)203-153(249)112(73-91-77-177-78-180-91)198-133(229)92(166)72-90-37-25-24-26-38-90;3-2(4,5)1(6)7/h24-26,37-38,77-89,92-115,126-129,210H,21-23,27-36,39-76,162-166H2,1-20H3,(H2,167,211)(H2,168,212)(H2,169,213)(H2,170,214)(H2,171,215)(H2,172,226)(H,177,180)(H,181,227)(H,182,230)(H,183,235)(H,184,239)(H,185,240)(H,186,241)(H,187,244)(H,188,250)(H,189,237)(H,190,231)(H,191,232)(H,192,233)(H,193,238)(H,194,234)(H,195,253)(H,196,254)(H,197,228)(H,198,229)(H,199,236)(H,200,247)(H,201,245)(H,202,246)(H,203,249)(H,204,251)(H,205,248)(H,206,255)(H,207,242)(H,208,243)(H,209,252)(H,216,217)(H,218,219)(H,220,221)(H,222,223)(H,224,225)(H4,173,174,178)(H4,175,176,179);(H,6,7)/t84-,85-,86-,87-,88-,89+,92+,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,126-,127-,128-,129-;/m0./s1
InChi Key
FHZQYUPGDABGJW-NDMSIQOJSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    500 µg

    $334

    Add

    1 mg

    $568

    Add
    Product Description

    Antisauvagine-30 is a peptide antagonist of corticotropin-releasing factor receptor 2 (CRF2).1,2 It is selective for CRF2α over CRF1 (Kis = 1.75 and 915 nM, respectively for the human receptors).1 Antisauvagine-30 (10 nM) inhibits sauvagine-induced cAMP production in HEK293 cells expressing mouse CRF2β.2 It prevents stress-induced contextual fear conditioning in mice.3 Antisauvagine-30 reduces vasoactive intestinal peptide-induced decreases in food intake in rats.4

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Dautzenberg, F.M., Py-Lang, G., Higelin, J., et al. Different binding modes of amphibian and human corticotropin-releasing factor type 1 and type 2 receptors: Evidence for evolutionary differences. J. Pharmacol. Exp. Ther. 296(1), 113-120 (2001).

    2. Rühmann, A., Bonk, I., Lin, C.R., et al. Structural requirements for peptidic antagonists of the corticotropin-releasing factor receptor (CRFR): Development of CRFR2β-selective antisauvagine-30. Proc. Natl. Acad. Sci. USA 95(26), 15264-15269 (1998).

    3. Sananbenesi, F., Fischer, A., Schrick, C., et al. Mitogen-activated protein kinase signaling in the hippocampus and its modulation by corticotropin-releasing factor receptor 2: A possible link between stress and fear memory. J. Neurosci. 23(36), 11436-11443 (2003).

    4. Garnica-Siqueira, M.C., Martins, A.B., Zaia, D.A.M., et al. Corticotrophin-releasing factor mediates vasoactive intestinal peptide-induced hypophagia and changes in plasma parameters. Horm. Behav. 105, 138-145 (2018).